GLP-1s

Page 2 of 2

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

February 4, 2025

A person stands on a scale.

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By Lindsey Leake

February 3, 2025

Ozempic and Wegovy medications side by side

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By The Associated Press, Kenya Hunter and Linley Sanders

January 31, 2025

The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By Lindsey Leake

January 29, 2025

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By Lindsey Leake

January 22, 2025

Close up of RFK Jr. speaking against a blue background

Health-care investors bank on Congress snarling RFK Jr.’s plans

January 17, 2025

Portrait of Crunch Fitness CEO Jim Rowley seated at Fortune's video studio.

The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’

By Jane Thier and Fortune Editors

January 16, 2025

A Walgreens store exterior with people walking by on the street

Walgreens CEO describes drawback of anti-shoplifting strategy: ‘When you lock things up…you don’t sell as many of them’

By Hallie Steiner

January 14, 2025

Most Popular